Colorcon acquires Paulaur Corporation’s pharmaceutical sugar spheres business
![](/46/pdcnewsitem/03/88/06/colorcon.jpg)
The addition of the Paulaur products complements Colorcon’s Suglets Sugar Spheres product line and enhances Colorcon’s position as a leading global supplier of sugar spheres for the development of multiparticulate dosages.
Colorcon has announced the acquisition of the Pharmaceutical Sugar Spheres product line from Paulaur Corporation, a manufacturer of specialty sugar‐based ingredients located in Cranbury, New Jersey.
The addition of the Paulaur products complements Colorcon’s Suglets Sugar Spheres product line and enhances Colorcon’s position as a leading global supplier of sugar spheres for the development of multiparticulate dosages. The agreement is specific to Paulaur sugar spheres sold into the pharmaceutical and nutritional segments globally.
Colorcon provides speciality excipients for pharmaceutical and nutraceutical applications worldwide, and has identified strong synergies between the multiparticulate and film coating businesses. Colorcon is well‐positioned to serve pharmaceutical and nutraceutical spheres customers thanks to its range of immediate, delayed and extended release coatings and previous investment in the multiparticulate business.
Pankaj Rege, General Manager for Colorcon Manufactured Products explains: “There is strong demand in the industry for a supplier who offers high quality product, application and formulation support with a multi‐facility business continuity plan. This acquisition complements Colorcon’s existing investment in its people, capabilities, and organization, which have consistently delivered superior products and services to Colorcon’s pharmaceutical and dietary supplement customers.”
Mitchell Stefaniak, Vice President and Chief Financial Officer of Paulaur Corporation, commented that “Paulaur had made the decision to leave the pharmaceutical and nutraceutical spheres arena to concentrate on our fast‐growing food and confectionary business. At the same time, we wanted to insure that our pharmaceutical and nutraceutical spheres customers could be assured of a continued availability of quality product. The sale to Colorcon provides our customers with just such a supplier.”
Martti Hedman, Colorcon’s CEO states: “Paulaur’s pharmaceutical sugar spheres business is an exciting strategic acquisition for Colorcon. This announcement comes at the end of another strong year for us, with growth across all business areas. Colorcon views this agreement as an opportunity to expand Colorcon's sugar spheres business and leverage our global distribution, technical service, and sales infrastructure."
Colorcon provides a full range of products and services for solid oral dosage formulations and continues to see growth in multiparticulate dosages forms, especially for geriatric and pediatric populations. Due to this agreement, Colorcon and Paulaur customers stand to benefit with direct access to products, technical service and support from Colorcon.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance